Trends in Targeted Therapy Usage in Inflammatory Bowel Disease : TRENDY Study of ENEIDA
Gómez-Labrador, C. (Universidad Autónoma de Madrid)
Ricart, Elena (Hospital Clínic i Provincial de Barcelona)
Iborra, Marisa (Hospital Universitari i Politècnic La Fe (València))
Iglesias-Flores, Eva (Hospital Universitario Reina Sofía (Còrdova, Espanya))
Martín-Arranz, M.D. (Universidad Autónoma de Madrid)
De Castro, Luisa (Instituto de Investigación Sanitaria Galicia Sur)
De Francisco, R. (Hospital Universitario Central de Asturias)
García-Alonso, F.J. (Hospital Universitario Río Hortega (Valladolid))
Sanahuja, A. (Hospital Clínic Universitari (València))
Gargallo-Puyuelo, C.J. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza)
Mesonero, Francisco (Hospital Universitario Ramón y Cajal (Madrid))
Casanova, M.J. (Universidad Autónoma de Madrid)
Mañosa i Ciria, Míriam (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Rivero, Montserrat (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria))
Calvo, M. (Hospital Universitario Puerta de Hierro Majadahonda (Madrid))
Sierra Ausín, Mónica (Complejo Asistencial Universitario de León)
González-Muñoza, Carlos (Institut de Recerca Sant Pau)
Calvet, Xavier (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
García-López, Santiago
Guardiola, Jordi (Institut d'Investigació Biomèdica de Bellvitge)
Arias García, L. (Hospital Universitario de Burgos)
Márquez Mosquera, Lucía (Institut Hospital del Mar d'Investigacions Mèdiques)
Gutiérrez Casbas, Ana (Hospital General Universitario de Alicante (Alacant, País Valencià))
Zabana, Yamile (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Navarro-Llavat, Mercè (Hospital de Sant Joan Despí Moisès Broggi)
Lorente Poyatos, Rufo (Hospital General Universitario de Ciudad Real)
Piqueras, Marta (Consorci Sanitari de Terrassa)
Torrealba, Leyanira (Hospital Universitari de Girona Doctor Josep Trueta)
Bermejo, Fernando (Hospital Universitario de Fuenlabrada ( Madrid))
Ponferrada Díaz, Ángel (Hospital Universitario Infanta Leonor)
Pérez-Calle, José L. (Hospital Universitario Fundación Alcorcón)
Barreiro de-Acosta, Manuel (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Tejido, Coral (Complexo Hospitalario Universitario de Ourense - CHUO)
Cabriada, José Luis (Hospital de Galdakao (Usansolo, Biscaia))
Marín-Jiménez, Ignacio (Universidad Complutense de Madrid)
Roncero, Oscar (Complejo Hospitalario la Mancha Centro)
Ber, Yolanda (Hospital Universitario San Jorge)
Fernández-Salazar, Luis (Universidad de Valladolid)
Camps Aler, B. (Hospital General de Granollers)
Lucendo, Alfredo J. (Hospital General de Tomelloso)
Llaó, Jordina (Althaia Xarxa Assistencial Universitaria de Manresa)
Bujanda, Luis (Hospital Universitario de Donostia (Sant Sebastià, País Basc))
Muñoz Villafranca, Carmen (Hospital Universitario de Basurto (Bilbao, Biscaia))
Domènech, Eugeni (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Chaparro, María (Universidad Autónoma de Madrid)
P. Gisbert, Javier (Universidad Autónoma de Madrid)
Universitat Autònoma de Barcelona

Date:	2024
Abstract:	Markers that allow for the selection of tailored treatments for individual patients with inflammatory bowel diseases (IBD) are yet to be identified. Our aim was to describe trends in real-life treatment usage. For this purpose, patients from the ENEIDA registry who received their first targeted IBD treatment (biologics or tofacitinib) between 2015 and 2021 were included. A subsequent analysis with Machine Learning models was performed. The study included 10,009 patients [71% with Crohn's disease (CD) and 29% with ulcerative colitis (UC)]. In CD, anti-TNF (predominantly adalimumab) were the main agents in the 1st line of treatment (LoT), although their use declined over time. In UC, anti-TNF (mainly infliximab) use was predominant in 1st LoT, remaining stable over time. Ustekinumab and vedolizumab were the most prescribed drugs in 2nd and 3rd LoT in CD and UC, respectively. Overall, the use of biosimilars increased over time. Machine Learning failed to identify a model capable of predicting treatment patterns. In conclusion, drug positioning is different in CD and UC. Anti-TNF were the most used drugs in IBD 1st LoT, being adalimumab predominant in CD and infliximab in UC. Ustekinumab and vedolizumab have gained importance in CD and UC, respectively. The approval of biosimilars had a significant impact on treatment.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Biologics ; Biosimilars ; Crohn's disease ; Inflammatory bowel disease ; Positioning ; Targeted therapy ; Trends ; Ulcerative colitis
Published in:	Pharmaceutics, Vol. 16 Núm. 5 (may 2024) , p. 629, ISSN 1999-4923

DOI: 10.3390/pharmaceutics16050629
PMID: 38794292

17 p, 2.2 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles